Advertisement

Topics

HemaCare Reports Full Year 2018 Results

05:10 EDT 26 Mar 2019 | Businesswire

HemaCare Corporation

HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, today announced operational highlights and financial results for the year ended December 31, 2018.

2018 Operational Highlights

  • HemaCare celebrated its 40th anniversary since being founded in 1978.
  • Significant revenue growth attributable to existing and new cell therapy and global customers and key distributors.
  • Product and services revenue growth was primarily due to customized cell isolation, processing and cryopreservation, and specialized collections of leukopaks and mobilized peripheral blood.
  • In November 2018, the company moved its global headquarters to Northridge, California. In this new facility, HemaCare doubled its donor collection capacity and on-site cell processing capabilities. Located at the 44-acre Harman Campus, in the heart of the San Fernando Valley, the 40,000-square-foot newly renovated facility reflects the company’s accelerated growth. This new location also expands HemaCare’s onsite GMP capabilities beyond collection to include four clean rooms enabling GMP cell processing, isolation, cryopreservation, and biobanking services to further support the development efforts of novel cellular therapies.
  • In November 2018, HemaCare announced its involvement as a provider of leukapheresis process development material for 100% of the current FDA-approved immunocellular therapies, Kymriah® (Novartis; Switzerland), Yescarta® (Kite, a Gilead Company; CA, USA), and PROVENGE® (sipuleucel-T) (Dendreon Pharmaceuticals LLC; CA, USA). During the development process, HemaCare worked collaboratively with each company to source healthy donors per project requirements. All leukapheresis material was collected and shipped following stringent standards as developed by the AABB and accepted by the FDA.
  • On November 26, 2018, collaboration discussions resulted in a strategic partnership with Charles River Laboratories subsidiary, Vital River, to provide the scientific community in China with direct access to healthy and disease-state human primary cells.
  • On December 20, 2018, OneBlood exercised its option to make the third tranche investment of $1.25 million in shares of HemaCare’s common stock at $3.44 per share.

Financial Results

  • For the year ended December 31, 2018, HemaCare reported total revenues of $28.5 million, compared to $20.2 million for the year ended December 31, 2017, representing an increase of $8.3 million, or approximately 41%. The increase in revenues was primarily derived from an increase in customer growth and product mix improvement.
  • Gross profit for the year ended December 31, 2018 was $15.7 million, or 55% of net revenues, compared to $10.6 million, or 53% of net revenues, for the year ended December 31, 2017.
  • For the year ended December 31, 2018, HemaCare’s income before tax benefit and expenses increased to $6.2 million, as compared to $3.4 million for the year ended December 31, 2017, representing an increase of $2.8 million or approximately 82%.
  • HemaCare’s net income for the year ended December 31, 2018 increased to $4.5 million, as compared to $4.4 million for the year ended December 31, 2017, which includes a one-time tax benefit of $1 million.
  • Capital expenditures increased by $6.2 million, net of tenant improvement allowance, at December 31, 2018 compared to $0.7 million at December 31, 2017, primarily due to the move to the new state-of-the-art facility.
  • As of December 31, 2018, HemaCare had $10.2 million in cash and cash equivalents compared to $9.3 million in cash at December 31, 2017.

For complete audited December 31, 2018 Financial Statements, please click here.

Pete van der Wal, HemaCare’s President and Chief Executive Officer, stated: “2018 was a transformative year for HemaCare. We celebrated the company’s 40th anniversary, successfully relocated the company to a state-of-the-art much larger facility, while simultaneously exceeding our financial growth targets. The multi-year sustained growth in revenue and earnings continues to validate HemaCare’s strategic focus on providing clients with superior purity, viability and functionality of the human biological cells they purchase from HemaCare.”

About HemaCare

HemaCare is a global leader in the customization of human-derived biological products and services for biomedical research, drug discovery and cellular therapy process development. The company’s network of FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor material is available to customers and for use within HemaCare’s isolation laboratory. Human biological material including peripheral blood, bone marrow, and cord blood is isolated into various primary cells types for fresh and frozen distribution. For over 40 years, HemaCare has developed an extensive registry of repeat donors and provides human-derived primary blood cells and tissues for biomedical and drug discovery research and cell therapy clinical trials, and supports commercialization with apheresis collections, directly enabling customers to advance both autologous and allogeneic cellular therapies.

For more information please visit www.hemacare.com.

Forward Looking Statements

This press release contains forward-looking statements. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. Forward-looking statements in this press release address plans for facility utilization, among other subjects. Forward-looking statements are inherently subject to risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, the following: the ability of our donors to provide sufficient quality source material; our ability and the ability of our suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; adverse developments in our customer-base or the markets we serve; results of the Company’s collaboration with strategic partners; adverse changes in regulatory, social and political conditions affecting our industry; our ability to timely and effectively implement 2019 staffing, operations, and product menu changes; our ability to manage growth; and general market, economic and business conditions. Forward-looking statements are made as of the date of this release, and we expressly disclaim any obligation or undertaking to update forward-looking statements.

 
HEMACARE CORPORATION
BALANCE SHEETS
   

ASSETS

December 31,

2018

2017

CURRENT ASSETS
Cash and cash equivalents $ 10,274,000 $ 9,251,000
Accounts receivable, net 4,776,000 2,959,000
Product inventories and supplies, net 3,299,000 2,520,000
Prepaid expenses 239,000 162,000
Other current assets   141,000     -  
 
TOTAL CURRENT ASSETS   18,729,000     14,892,000  
 
OTHER ASSETS
Property and equipment, net 9,502,000 1,358,000
Deferred income taxes - 1,128,000
Other assets   -     70,000  
 
TOTAL NONCURRENT ASSETS   9,502,000     2,556,000  
 
TOTAL ASSETS $ 28,231,000   $ 17,448,000  
 

LIABILITIES AND SHAREHOLDERS' EQUITY

 
CURRENT LIABILITIES
Accounts payable $ 2,184,000 $ 682,000
Accrued payroll and payroll taxes 1,979,000 1,658,000
Other accrued expenses 123,000 210,000
Current portion of deferred rent - 9,000
Current portion of capital lease obligations   201,000     99,000  
 
TOTAL CURRENT LIABILITIES   4,487,000     2,658,000  
 
LONG-TERM LIABILITIES
Deferred rent, net of current portion 2,409,000 -
Deferred income taxes 35,000 -
Long-term portion of capital lease obligations   176,000     93,000  
 
TOTAL LONG-TERM LIABILITIES   2,620,000     93,000  
 
TOTAL LIABILITIES   7,107,000     2,751,000  
 

COMMITMENTS AND CONTINGENCIES

 
SHAREHOLDERS' EQUITY

Common stock, no par, 40,000,000 shares authorized, 12,860,956 and 12,011,545 shares issued and outstanding, respectively

23,060,000 21,149,000
Accumulated deficit   (1,936,000 )   (6,452,000 )
 
TOTAL SHAREHOLDERS' EQUITY   21,124,000     14,697,000  
 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 28,231,000   $ 17,448,000  
 
 
HEMACARE CORPORATION
STATEMENTS OF INCOME
FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017
   

2018

2017

 
REVENUE $ 28,506,000 $ 20,212,000
 
COST OF REVENUE   12,840,000     9,594,000
 
GROSS PROFIT 15,666,000 10,618,000
 
GENERAL AND ADMINISTRATIVE EXPENSES   9,434,000     7,195,000
 
INCOME BEFORE INCOME TAX BENEFIT (EXPENSE) 6,232,000 3,423,000
 
Income tax benefit (expense)   (1,716,000 )   1,009,000
 
NET INCOME $ 4,516,000   $ 4,432,000

HemaCare Media Contact:
Rochelle Martel
818-728-8868
rmartel@hemacare.com

NEXT ARTICLE

More From BioPortfolio on "HemaCare Reports Full Year 2018 Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...